Shanghai ImmuneOnco Biopharma completed an $89 million Series C funding led by Guangdong 's Greater Homeland Bay Area Investments and Lilly Asia Ventures. Founded in 2015, ImmuneOnco has established discovery platforms that exploit two types of innate immune cells: macrophages and natural killer (NK) cells. The company has been approved to start two clinical trials: IMM01, an anti-CD47 fusion protein, was approved in China , and IMM0306, a bispecific antibody targeting CD47 and CD20, was approved in the US . More details.... Share this with colleagues: // //